Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur CLAIRE MARTIN

📍 La Rochelle (17)HospitalierRPPS 10005154553
📊 Reconnaissance scientifique : 38/100📝 301 articles publiés📚 HAL (8)🏆 1 DU/DIU

✨ Profil synthétique

IA · 01/05/2026

Le Docteur Claire Martin est une rhumatologue hospitalière à La Rochelle, titulaire d'un DIU EA-PR/MAI. Elle est une chercheuse prolifique avec un h-index de 38 et 301 publications. Ses travaux de recherche portent principalement sur les troubles du rythme cardiaque et l'électrophysiologie cardiaque.

Expertises présumées

  • Épidémiologie des maladies rhumatismales
  • Essais cliniques en rhumatologie
  • Pédiatrie rhumatologique
  • Pharmacovigilance en rhumatologie
  • Gériatrie rhumatologique
  • Revue et méta-analyse en rhumatologie

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

Diplômes

🎓 DES & spécialité ordinale

  • DES Rhumatologie
  • Rhumatologie (SM)

🏅 DU / DIU

  • DIU Etudes approfondies polyarthrites-maladies

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

🏆 DU / DIU rhumato reconnus

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

38

h articles cités ≥ h fois chacun. Un h de 38 = 38 publications avec 38+ citations.

Citations

4 962

Publications

301

i10-index

100

Thématiques principales

  • Cardiac Arrhythmias and Treatments ×134
  • Atrial Fibrillation Management and Outcomes ×97
  • Cardiac electrophysiology and arrhythmias ×74
  • Cardiac pacing and defibrillation studies ×52
  • Ion channel regulation and function ×16

Affiliations FR : Université de Limoges

Voir sur OpenAlex ↗🆔 ORCID 0000-0001-7755-3613

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

  • HOPITAL SAINT-LOUIS - LA ROCHELLE

    Rue DU DR SCHWEITZER, 17019 La Rochelle

    ☎ 0546455050Hospitalier

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study

    Nature medicine · 2024

    📚 335 citations🎯 RCR 97.77Top 0% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    AbstractPulsed field ablation (PFA) is an emerging technology for the treatment of atrial fibrillation (AF), for which pre-clinical and early-stage clinical data are suggestive of some degree of preferentiality to myocardial tissue ablation without damage to adjacent structures. Here in the MANIFEST-17K study we assessed the safety of PFA by studying the post-approval use of this treatment modality. Of the 116 centers performing post-approval PFA with a pentaspline catheter, data were received from 106 centers (91.4% participation) regarding 17,642 patients undergoing PFA (mean age 64, 34.7% female, 57.8% paroxysmal AF and 35.2% persistent AF). No esophageal complications, pulmonary vein stenosis or persistent phrenic palsy was reported (transient palsy was reported in 0.06% of patients; 11 of 17,642). Major complications, reported for ~1% of patients (173 of 17,642), were pericardial tamponade (0.36%; 63 of 17,642) and vascular events (0.30%; 53 of 17,642). Stroke was rare (0.12%; 22 of 17,642) and death was even rarer (0.03%; 5 of 17,642). Unexpected complications of PFA were coronary arterial spasm in 0.14% of patients (25 of 17,642) and hemolysis-related acute renal failure necessitating hemodialysis in 0.03% of patients (5 of 17,642). Taken together, these data indicate that PFA demonstrates a favorable safety profile by avoiding much of the collateral damage seen with conventional thermal ablation. PFA has the potential to be transformative for the management of patients with AF.

  • 2
    The BLISTER Score: A Novel, Externally Validated Tool for Predicting Cardiac Implantable Electronic Device Infections, and Its Cost-Utility Implications for Antimicrobial Envelope Use

    Circulation. Arrhythmia and electrophysiology · 2024

    📚 25 citations🎯 RCR 7.21Top 4% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    BACKGROUND: Antimicrobial envelopes reduce the incidence of cardiac implantable electronic device infections, but their cost restricts routine use in the United Kingdom. Risk scoring could help to identify which patients would most benefit from this technology. METHODS: A novel risk score (BLISTER [Blood results, Long procedure time, Immunosuppressed, Sixty years old (or younger), Type of procedure, Early re-intervention, Repeat procedure]) was derived from multivariate analysis of factors associated with cardiac implantable electronic device infection. Diagnostic utility was assessed against the existing PADIT score (Prior procedure, Age, Depressed renal function, Immunocompromised, Type of procedure) in both standard and high-risk external validation cohorts, and cost-utility models examined different BLISTER and PADIT score thresholds for TYRX (Medtronic; Minneapolis, MN) antimicrobial envelope allocation. RESULTS: In a derivation cohort (n=7383), cardiac implantable electronic device infection occurred in 59 individuals within 12 months of a procedure (event rate, 0.8%). In addition to the PADIT score constituents, lead extraction (hazard ratio, 3.3 [95% CI, 1.9–6.1]; P <0.0001), C-reactive protein >50 mg/L (hazard ratio, 3.0 [95% CI, 1.4–6.4]; P =0.005), reintervention within 2 years (hazard ratio, 10.1 [95% CI, 5.6–17.9]; P <0.0001), and top-quartile procedure duration (hazard ratio, 2.6 [95% CI, 1.6–4.1]; P =0.001) were independent predictors of infection. The BLISTER score demonstrated superior discriminative performance versus PADIT in the standard risk (n=2854, event rate: 0.8%, area under the curve, 0.82 versus 0.71; P =0.001) and high-risk validation cohorts (n=1961, event rate: 2.0%, area under the curve, 0.77 versus 0.69; P =0.001), and in all patients (n=12 198, event rate: 1%, area under the curve, 0.8 versus 0.75, P =0.002). In decision-analytic modeling, the optimum scenario assigned antimicrobial envelopes to patients with BLISTER scores ≥6 (10.8%), delivering a significant reduction in infections (relative risk reduction, 30%; P =0.036) within the National Institute for Health and Care Excellence cost-utility thresholds (incremental cost-effectiveness ratio, £18 446). CONCLUSIONS: The BLISTER score ( https://qxmd.com/calculate/calculator_876/the-blister-score-for-cied-infection ) was a valid predictor of cardiac implantable electronic device infection, and could facilitate cost-effective antimicrobial envelope allocation to high-risk patients.

  • 3
    First-in-human results of terbium-161 [(161)Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

    The Lancet. Oncology · 2025

    📚 21 citations🎯 RCR 8.52🩺 Clinique

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal36

▼

Épidémiologie & registres3

▼

Essai clinique2

▼

Pédiatrie2

▼

Pharmacovigilance2

▼

Revue / méta-analyse2

▼

Gériatrie1

▼

IA en rhumatologie1

▼

Recommandations1

▼

Revue générale1

▼

Vascularites1

▼

Vraie vie / RWE1

▼

Datasets & protocoles partagés

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.